After 15 years of clinical testing and analyses of biopsies from patients with cancers treated with antibodies blocking the programmed death receptor 1 (PD-1) pathway, several requirements for inducing durable clinical responses have become evident. T…
Chimeric antigen receptor (CAR) therapies have revolutionized cancer treatment by enabling immune cells to target tumor cells with high specificity. While extensive research has focused on optimizing single-chain variable fragment (scFv) affinity in C…
Immune checkpoint inhibition (ICI) targeting programmed cell death protein-1 (PD1) prevents the elimination of activated cytotoxic T lymphocytes (CTLs) by programmed death-ligand 1/2-expressing cancer and myeloid cells in the tumor microenvironment (T…
Hormone-dependent cancers, like breast and prostate cancers, represent a unique challenge in oncology due to their complex interplay between hormone signaling, immune evasion, and therapeutic resistance. While endocrine therapies effectively target ho…
Opioids remain a mainstay for managing moderate-to-severe cancer pain, yet accumulating evidence suggests that opioid analgesics can impair antitumor immunity. In their recent study, McIlvried et al propose a mechanistic framework for how morphine adm…
Asia’s role in cancer immunotherapy research is rapidly expanding, driven by cutting-edge facilities, innovative technologies, and collaborative efforts. This commentary examines the region’s growing impact, highlighting key clinical trial…
Resident Golgi protein 73 (GP73) is expressed in many healthy tissues, however overexpression is associated with both viral infections and cancer. As an oncoprotein, GP73 drives tumor progression and plays a fundamental role in immune regulation. A re…
Metrnl (Meteorin-like), a protein elevated by exercise, supports metabolic regulation, inflammation reduction and glucose homeostasis. While exercise is a cornerstone of cancer prevention and management, recent findings suggest that Metrnl plays a dua…
Clinical success in the therapeutic targeting of the CD47 signaling pathway has thus far remained elusive despite a promising scientific rationale. Use of oncolytic viruses to deliver CD47 targeting agents represents a novel approach to modulate the i…
A tumor’s ability to attract innervation is a critical factor in tumor progression and immune escape, with the sympathetic nervous system playing a major role. Catecholamines released by sympathetic nerves activate adrenergic receptors on tumor …
